AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...
Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA) to ...
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...
Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.
“Ulcerative colitis can severely diminish a person’s quality of life and cause long-term health-related complications if it isn’t well managed,” said Professor Charlie Lees, Consultant ...
Sales of Skyrizi and Rinvoq grew by 50% and 45%, respectively -- much faster than any other medicine in the company's portfolio, even though they generate the highest sales aside from Humira.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback